
Releases
Investors Face August Deadline in ADMA Biologics Securities Lawsuit
Investors in ADMA Biologics have until August 10, 2026, to petition the U.S. District Court for the District of New Jersey for lead plaintiff status in a pending class action lawsuit. The litigation follows accusations that the biopharmaceutical company artificially inflated its revenue through deceptive channel stuffing practices.


























